Ventrus BioSciences Analyst Report by BrokerBank Securities, Inc.

NEW YORK, June 16, 2014 /PRNewswire/ -- Ventrus BioSciences, Inc. VTUS is a development-stage specialty pharmaceutical company currently focused on the development of gastrointestinal products, including infections of the gastrointestinal system. Out of the four product candidates the company has in-licensed, VTUS is actively developing only two of them right now. These candidates include VEN 307, a diltiazem cream for the relief of pain associated with anal fissures, and VEN 310 for use as a colonic delivery mechanism, which is a pH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules and other treatments to the gastrointestinal tract. In addition, VTUS intends to in-license or acquire other development stage and pre-clinical compounds and biologics.

Gastrointestinal or gastroenterology is the branch of medicine related to the gastrointestinal tract (see: stomach and intestines) and the accessory organs of digestion from the mouth to the anus. Overall, the market for gastrointestinal products is fairly large with considerable progress having been made over the years in several areas such as gastroesophageal reflux, peptic ulcer disease and inflammatory bowel disease (IBD). However, many major gastrointestinal disorders offer few medical treatment options while some still lack treatments altogether. It is here that VTUS believes it can make some strides.

Although not a huge market, it is estimated there are approximately 1.1 million office visits per year for anal fissures in the United States, while the British Medical Journal Best Practice estimates that the incidence of anal fissures in adults is around 1 in 350. Despite these figures, there is currently only one drug that has received US Food and Drug Administration (FDA) approval for the treatment of pain associated with anal fissures and that is Rectiv, which is a prescription nitroglycerin ointment. Although Rectiv is effective in reducing pain, an oft-cited side effect is moderate to severe headaches stemming from the drug's active ingredient – nitroglycerin.

A full in-depth analyst report on VTUS that includes company overview, market and competition, allocation of resources, royalty agreements, financials, analyst summary, and recommendation can be viewed by using the following link at no cost:

http://bit.ly/-VTUS-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER   

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.   

COMPLIANCE PROCEDURE   

Content is researched, written and reviewed on a best-effort basis. Research report provided for informational purposes. This document, article or report is written and authored by Michael Maggi, Chartered Financial Analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

A full disclaimer can be found by viewing the full analyst report.

BrokerBank Securities, Inc. is a member of the Financial Industry Regulatory Authority, CRD number #130116.

SOURCE BrokerBank Securities, Inc.